Home › Chronic Lymphocytic Leukemia › Connecticut
Chronic Lymphocytic Leukemia clinical trials in Connecticut
4 studies for Chronic Lymphocytic Leukemia are looking for participants at sites in Connecticut.
Cities in Connecticut
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
- Yale University Yale Cancer Center, New Haven
- Eastern Connecticut Hematology and Oncology, Norwich
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT06943872A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
- Eastern CT Hematology & Oncology Associates ( Site 0033), Norwich
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT06136559A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
- Yale Cancer Center, New Haven
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 2, 2026 · NCT05131022A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
- Yale University School of Medicine /ID# 266224, New Haven
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Apr 9, 2026 · NCT06428019From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.